Please use this identifier to cite or link to this item:
Title: New Agents for the Treatment of Type 2 Diabetes.
Austin Authors: Libianto, Renata;Ekinci, Elif I 
Affiliation: Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Apr-2019 2019-01-23
Publication information: Critical care clinics 2019; 35(2): 315-328
Abstract: The Renaissance of glucose-lowering therapies has arrived with multiple agents that lower blood glucose and demonstrate cardiovascular and renal benefits in people with type 2 diabetes. This article summarizes these new classes of therapies, including the sodium glucose co-transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors. Their cardiovascular safety profile, effects on glycemic, weight, and renal outcomes are discussed. As more options become available to treat type 2 diabetes, clinicians need to be aware of the advantages of each class of medications, beyond their glycemic lowering effects. The safety profiles are summarized in this article.
DOI: 10.1016/j.ccc.2018.11.007
ORCID: 0000-0003-2372-395X
PubMed URL: 30784612
Type: Journal Article
Subjects: DPP-4 inhibitors
GLP-1 agonists
New treatment
SGLT-2 inhibitors
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.